Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Funding cuts and regulatory changes could radically reduce Medicaid, the largest program providing medical and health-related ...
The newly installed Trump administration late Tuesday prompted federal health agencies, including the Centers for Medicare & Medicaid Services (CMS), ...
The feds intend to appeal a judge's decision that would force them to recalculate UnitedHealthcare's Medicare Advantage (MA) ...
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...
Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback